Telomir Pharmaceuticals, Inc. Common Stock (TELO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Telomir Pharmaceuticals, Inc. Common Stock (TELO) has a cash flow conversion efficiency ratio of -0.357x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.77 Million) by net assets ($4.96 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See how leveraged is Telomir Pharmaceuticals, Inc. Common Sto's balance sheet to measure how much of total assets are equity-financed.
Telomir Pharmaceuticals, Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2021–2025)
This chart illustrates how Telomir Pharmaceuticals, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore TELO operating cash flow to total debt to assess how comfortably operating cash covers total debt obligations.
Telomir Pharmaceuticals, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Telomir Pharmaceuticals, Inc. Common Stock ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
MFEC PCL
BK:MFEC
|
-0.071x |
|
Western Energy Services Corp.
TO:WRG
|
0.027x |
|
Weir Group PLC
LSE:WEIR
|
0.129x |
|
Mirae Asset Daewoo Special Purpose Acquisition Company 4 Co. Ltd
KQ:333430
|
0.030x |
|
RGB International Bhd
KLSE:0037
|
0.068x |
|
Elite Naturel Organik Gida Sanayi ve Ticaret AS
IS:ELITE
|
-0.007x |
|
Les Docks des Pétroles d-Ambès - SA
PA:DPAM
|
0.067x |
|
Say Yenilenebilir Enerji Ekipmanları Sanayi ve Ticaret Anonim Şirketi
IS:SAYAS
|
0.025x |
Annual Cash Flow Conversion Efficiency for Telomir Pharmaceuticals, Inc. Common Stock (2021–2025)
The table below shows the annual cash flow conversion efficiency of Telomir Pharmaceuticals, Inc. Common Stock from 2021 to 2025. For the full company profile with market capitalisation and key ratios, see TELO market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-09-30 | $5.91 Million | $-3.69 Million | -0.624x | +92.09% |
| 2024-09-30 | $643.04K | $-5.07 Million | -7.885x | -602.39% |
| 2023-09-30 | $3.44 Million | $-3.86 Million | -1.123x | -324.51% |
| 2022-09-30 | $-937.28K | $-468.66K | 0.500x | -65.19% |
| 2021-09-30 | $-83.13K | $-119.40K | 1.436x | -- |
About Telomir Pharmaceuticals, Inc. Common Stock
Telomir Pharmaceuticals, Inc., a preclinical-stage biotechnology company, focuses on the development of small-molecule therapeutics designed to address upstream biological drivers of aging and age-related diseases. It is developing Telomir-1, an oral small molecule metal ion regulator designed to protect against age-related conditions, including Wilson's disease, Type 2 diabetes, age-related macu… Read more